Enliven Therapeutics Inc (ELVN) Hedge Fund & Institutional Holdings (Q2 2026)

ELVN ranks #2822 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ELVN is a top-conviction position for Commodore Capital LP — at 9.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ELVN belongs to FMR LLC, but the position matters far more to Commodore Capital LP, who has 9.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

GAMMA Investing LLC has added to its ELVN position for two straight quarters, increasing it by $11.8K to reach $20.5K today.

ELVN is down 5.1% today, but institutions show net buying of $1.1B this quarter — a divergence between today's price move and the underlying institutional flow.

ELVN reported a net loss of $103.7M in its latest fiscal year.

• Not yet profitable — net loss of $103.7M in the latest fiscal year
• Net income declined year over year, from -$89.0M to -$103.7M
• Operating cash flow was negative, using $70.3M in cash
• Current ratio of 28.66x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.04x equity — within a conventional range